Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,901–2,000 of 2,517
Autoantibody recognition mechanisms of p53 epitopes
Phillips, J. C. (2016) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2016.01.021 · Cited by 5
Alam, S., Sayem, M., Bello, M., Mou, S. I., Faruqui, N. A., Hossain, F., & Hasan, M. K. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00859-0 · Cited by 5
“Amino acid substitution in the sequence of the functional domain may lead to alterations of the protein structures (Cho et al. 1994).”
BackgroundHephzibah Cathryn, R., & Doss, C. G. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2283793 · Cited by 5
“…shorter imidazolium side chain, would not attach to DNA as effectively as ARG 273 due to the break-down of the hydrogen bonds between the ARG 273 side chain and Thymidine 7 phosphate (OP2) during mutation (Cho et al., 1994; Kamaraj et al., 2015; Kamaraj & Bogaerts, 2015; Kholmirzo et al., 2011).”
Viscuse, P. V., Tidwell, R. S. S., Zhang, M., Rohra, P., Zhu, K., Lucas, F. A. S., Konnick, E. Q., Pilie, P. G., Siddiqui, B. A., Logothetis, C. J., et al. (2023) · Cancers · doi:10.3390/cancers15245843 · Cited by 5
“TP53 alterations in prostate cancer are often missense mutations within the DNA-binding domain, resulting in p53 nuclear accumulation in IHC [16–18].”
BackgroundBuchberg, J., de Stricker, K., Pfeiffer, P., Mortensen, M. B., & Detlefsen, S. (2024) · Endoscopic Ultrasound · doi:10.1097/eus.0000000000000072 · Cited by 9
Peris‐Díaz, M. D., Krężel, A., & Barran, P. E. (2025) · Communications Chemistry · doi:10.1038/s42004-024-01395-w · Cited by 8
“The crystal structure of p53-DBD in complex with DNA reveals that R248 interacts with the minor groove of DNA, and therefore, R248Q is referred to as a DNA-contact mutant 3 .”
Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53
Taritsa, I. C., & Fossel, E. T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529483 · Cited by 7
Kratochvilová, L., Dinová, A., Valková, N., Dobrovolná, M., Sánchez‐Murcia, P. A., & Brázda, V. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.4c00124 · Cited by 8
Naeem, W., Nawab, F., Sarwar, M. T., Khalil, A. T., Gaber, D. A., Ahmad, H., Fazeel, M., Alorini, M., Khan, I. A., Irfan, M. I., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-91700-x · Cited by 9
“These OSCC patient findings are similar to previous literature of TP53 mutations in other cancers 60,61 .”
Wang, T., Shao, X., Cai, W., Xue, Y., Wang, S., & Feng, X. (2010) · Physical Chemistry Chemical Physics · doi:10.1039/c0cp00678e · Cited by 5
Network Analysis of Molecular Dynamics Sectors in the p53 Protein
Fabry, J. D., & Thayer, K. M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05635 · Cited by 6
Vávra, J., Sergunin, A., Pompach, P., Savchenko, D. V., Hraníček, J., Šloufová, I., Shimizu, T., & Martínková, M. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112180 · Cited by 5
Balasundaram, A., Kumar, S. U., Kumar, D. T., Dedge, A. A., Ramanathan, G., Kondaveeti, S. S., Ramamoorthy, S., & Doss, C. G. P. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2191122 · Cited by 6
“The R175H hotspot mutation at the DNA binding domain interface alters the protein structure, consequently interrupting its stability (Cho et al., 1994).”
BackgroundKugler, V., Lieb, A., Guerin, N., Donald, B. R., Stefan, E., & Kaserer, T. (2023) · Communications Biology · doi:10.1038/s42003-023-05089-2 · Cited by 5
Pervushin, N. V., Nilov, D. K., Pushkarev, S. V., Shipunova, V. O., Станиславовна, Б. А., Yapryntseva, M. A., Kopytova, D. V., Zhivotovsky, B., & Kopeina, G. S. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02014-8 · Cited by 9
Analysis of p53 mutations and Helicobacter pylori infection in human and animal models
Murakami, K., Fujioka, T., Kodama, M., et al. (2001) · Gastroenterology · doi:10.1016/s0016-5085(08)83713-4 · Cited by 5
Release of targeted p53 from the mitochondrion as an early signal during mitochondrial dysfunction
Green, M. L., Pisano, M., Prough, R. A., & Knudsen, T. B. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.019 · Cited by 6
Feature Multiplexing—Improving the Efficiency of Microarray Devices
Schmid, M. J., Manthiram, K., Grayson, S. M., et al. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502151 · Cited by 5
The Three-Dimensional Structure of p53
Stavridi, E. S., Huyen, Y., Sheston, E. A., & Halazonetis, T. D. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_2 · Cited by 7
“The p53 residues that are key to its interaction with 53BP1, Arg248 and Arg249, are highly conserved in evolution; however, the evolutionary conservation may reflect the importance of these residues for sequence-specific DNA binding (Cho et al., 1994).”
BackgroundMethodInfluentialA chimeric protein PTEN-L-p53 enters U251 cells to repress proliferation and invasion
Xiao, M., An, Y., Wang, F., Yao, C., Zhang, C., Xin, J., Duan, Y., Zhao, X., Fang, N., & Ji, S. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.05.023 · Cited by 6
Phosphomimetic Mutation Destabilizes the Central Core Domain of Human p53
Luwang, J. W., & NATESH, R. (2018) · IUBMB Life · doi:10.1002/iub.1914 · Cited by 6
Joerger, A. C. (2018) · Structure · doi:10.1016/j.str.2018.08.008 · Cited by 5
Ahmadi, S., Saffari, M., Modarressi, M. H., Shirkoohi, R., Jamalian, M., & Teimori, H. (2019) · International Journal of Cancer Management · doi:10.5812/ijcm.88829 · Cited by 5
“This gene plays an important role in suppressing the tumor, stopping the cell cycle, inducing apoptosis, and inhibiting angiogenesis (26).”
BackgroundToward Cancer Diagnostics of the Tumor Suppressor p53 by Surface Enhanced Raman Spectroscopy
Bizzarri, A. R., & Cannistraro, S. (2020) · Sensors · doi:10.3390/s20247153 · Cited by 5
“Figure 1a shows a graphical representation of the DBD portion of p53wt from 1 TUP entry of the protein data bank (PDB) [50]; the positions of amino acids susceptible to be mutated in our investigation are marked (see legend of Figure 1).”
BackgroundInfluentialYang, D., Huang, K., Su, M., et al. (2021) · Journal of International Medical Research · doi:10.1177/03000605211018575 · Cited by 5
“A159P mutation was located at the DNA-binding domain and was predicted as a pathogenic mutation that disrupts the structure of the b-sandwich.(18,19) In the right lesion, a TP53 c.”
BackgroundLow‐frequency collective motion of DNA ‐binding domain defines p53 function
Zhang, G., Tang, C., Pan, L., & Lü, J. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26283 · Cited by 5
Ding, L. J., Zhao, C., Xu, Y., Zhang, Z., Nie, Y., Liao, K., Chen, Y., Tu, B., & Zhang, X. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113211 · Cited by 6
Akhmetova, V. R., Galimova, E. M., Mescheryakova, E. S., et al. (2023) · Metallomics · doi:10.1093/mtomcs/mfad037 · Cited by 5
Akshatha, H. S., Bhagyalalitha, M., Pujar, G. V., Hariharapura, R. C., Sethu, A. K., Singh, M., & Bidye, D. P. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0061 · Cited by 8
Correcting errors in the BRCA1 warning system
Liang, Y., Dearnaley, W. J., Alden, N. A., Solares, M. J., Gilmore, B. L., Pridham, K. J., Varano, A. C., Sheng, Z., Alli, E., & Kelly, D. F. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.11.009 · Cited by 5
Lefrou, L., Godart, B., Muret, A. D., Scotto, B., & Dorval, E. D. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73212-2 · Cited by 5
Fijal, B. A., Idury, R. M., & Witte, J. S. (2002) · Statistics in Medicine · doi:10.1002/sim.1145 · Cited by 5
Protopopova, M., & Selivanova, G. (2003) · Cell Cycle · doi:10.4161/cc.2.6.501 · Cited by 6
In vitro folding and characterization of the p53 DNA binding domain
Klein, C., Hesse, F., Dehner, A., Engh, R. A., Schwaiger, M., & Hansen, S. (2004) · Biological Chemistry · doi:10.1515/bc.2004.012 · Cited by 5
“The crystal structure of the p53 DNA binding domain (p53DBD) in complex with its consensus DNA demonstrated how p53 is inactivated by ’hot spot mutations’ and illustrated the central role of a Zn2 cation for the folding of the domain (Pavletich et al., 1993; Cho et al., 1994; Zhao et al., 2001).”
BackgroundDouillet, C., Tabib, A., Bost, M., Accominotti, M., Borson‐Chazot, F., & Ciavatti, M. (1999) · The Journal of Trace Elements in Experimental Medicine · doi:10.1002/(sici)1520-670x(1999)12:4<375::aid-jtra11>3.0.co;2-r · Cited by 25
Scintillation Proximity Assay for DNA Binding by Human p53
Gal, S., Cook, J. R., & Howells, L. (2006) · BioTechniques · doi:10.2144/000112222 · Cited by 5
Takahashi, M., Tonoki, H., Tada, M., et al. (2001) · Medical Entomology and Zoology · Cited by 5
Neuropathology and Molecular Pathogenesis of Primary Brain Tumors
Mischel, P. S., & Vinters, H. V. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-035-3_1 · Cited by 6
Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer
Rosell, R., O’Brate, A., Monzó, M., et al. (2001) · Revista de Oncología · doi:10.1007/bf02711456 · Cited by 5
Robbins, P. (1996) · International Journal of Surgical Pathology · doi:10.1177/106689699600400206 · Cited by 5
Kutscher, B. (1995) · Nachrichten aus Chemie Technik und Laboratorium · doi:10.1002/nadc.19950430209 · Cited by 5
Dehner, A., Klein, C., Hansen, S., Müller, L., Büchner, J., Schwaiger, M., & Kessler, H. (2005) · Angewandte Chemie · doi:10.1002/ange.200501887 · Cited by 5
Exon Concatenation to Increase the Efficiency of Mutation Screening by DGGE
Agirre, X., Garcí-Delgado, M., Calasanz, M. J., et al. (2002) · BioTechniques · doi:10.2144/02325rr01 · Cited by 5
Reactive Oxygen Species in the Activation and Regulation of Intracellular Signaling Events
Chen, F. (2004) · Lung biology in health and disease · doi:10.1201/b14147-4 · Cited by 6
Mesoscopic Liquid Clusters Represent a Distinct Condensate of Mutant p53Preprint
Yang, D. S., Saeedi, A., Davtyan, A., Fathi, M., Safari, M., Klindziuk, A., Barton, M., Varadarajan, N., Kolomeisky, A., & Vekilov, P. (2020) · bioRxiv · doi:10.1101/2020.02.04.931980 · Cited by 5
Zhao, L., Punga, T., & Sanyal, S. (2025) · eLife · doi:10.7554/elife.106469 · Cited by 6
Liu, Q., Yu, Y., & Wei, G. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp02046d · Cited by 5
Khurshid, I., Mehraj, T., Maqbool, A., Aejaz, K., Khursheed, A., Rather, M. A., Ahmed, S. S. S. J., & Dangroo, N. A. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100143 · Cited by 4
Hunter, C. J., Im, A., & Shallis, R. M. (2026) · Cancers · doi:10.3390/cancers18020275 · Cited by 6
“…via MAPK signaling [49]; the primary DNA-binding domain (DBD), which is critical for its genome surveillance activity [50,51]; the homo-oligomerization domain (HOD), which helps form the biologically active tetrameric form of p53 [52]; and the C-terminal domain, which modulates the DBD [53,54].”
Roney, M., Hisam, N. S. M., Uddin, M. N., Hamim, S. M. I., Lim, L. W., & Wong, K.-H. (2026) · Scientific Reports · doi:10.1038/s41598-025-30652-8 · Cited by 6
Oljačić, S., Popovic-Nikolic, M., Filipić, B., Gagić, Ž., & Nikolic, K. M. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266337668241025061804 · Cited by 5
Mechanistic Insights of a p53-Targeting Small Molecule
Ferreira, R. J., Barcherini, V., Roma‐Rodrigues, C., Sikorová, M., Saraiva, L., Leandro, P., Baptista, P. V., Fernandes, A. R., Antunes, A. M. M., & Santos, M. M. M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00110 · Cited by 5
Tracewell, M., Karlin, J., Barnada, S. M., McDuffie, E., Scott, C. P., Barta, J. A., & McMahon, S. B. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf027 · Cited by 4
Stability of p53 oligomers: Tetramerization of p53 impinges on its stability
Luwang, J. W., Nair, A. R., & NATESH, R. (2021) · Biochimie · doi:10.1016/j.biochi.2021.06.012 · Cited by 5
Qiao, G., Pan, X., He, M., Peng, R., Huang, X., Nie, C., Jiang, J., & Chu, X. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.146449 · Cited by 4
Ghosh, A., & Ganguly, D. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2279270 · Cited by 5
“…proline-rich domain, DNA-binding domain, nuclear localization signaling domain, tetra-merization domain, and C-terminal negative regulatory domain (Cho et al., 1994; Clore et al., 1995; Fields & Jang, 1990; Joerger & Fersht, 2007; Lee et al., 1994; 2000; R € omer et al., 2006; Wells et al., 2008)…”
张德楠, Su, Y., Wang, Y., Qu, Z., Liu, J., Ren, X., & Chen, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1280099 · Cited by 5
Han, I. S. M., & Thayer, K. M. (2024) · ACS Omega · doi:10.1021/acsomega.3c08509 · Cited by 7
Zhou, H., & Yan, S. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110210 · Cited by 5
Highlights Of P53 Mutation And It's Role In Cervical Cancer Metastasis
Gracy.G, S. K. (2014) · Cited by 4
Sequestering of p53 into DNA–protein filaments revealed by electron microscopy
Cherny, D. I., Brázdová, M., Palecek, J. J., et al. (2005) · Biophysical Chemistry · doi:10.1016/j.bpc.2004.12.042 · Cited by 4
“The common feature is presumed to be a decamer target 5V-PuPuPuC (A/T)(T/A)GPyPyPy-3V (two head-to-head quarter sites; Pu, purines, and Py, pyrimidines) [14,21,24–26], with two consecutive decamers constituting the consensus sequence.”
Background4.10 Nanosafety Issues of Nanomaterials
Leong, D. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803581-8.09321-8 · Cited by 4
Bromley, D., & Daggett, V. (2020) · Protein Science · doi:10.1002/pro.3921 · Cited by 5
“Calculations involving DNA-contacting residues used Residues 120, 241, 248, 273, 276, 277, 280, and 283.(30) The L1/H2 distance was measured between the Cα atoms of K120 and R280.”
MethodBizzarri, A. R., & Cannistraro, S. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c06778 · Cited by 3
Meneghetti, B. V., Wilson, R., Dias, C. K., Cadore, N. A., Klamt, F., Zaha, A., Ferreira, H. B., & Monteiro, K. M. (2022) · Biochimie · doi:10.1016/j.biochi.2022.03.003 · Cited by 5
Jurneczko, E., Cruickshank, F. L., Porrini, M., Clarke, D. J., Campuzano, I. D. G., Morris, M. R., Nikolova, P. V., & Barran, P. E. (2013) · Angewandte Chemie · doi:10.1002/ange.201210015 · Cited by 5
VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS
Chang, F.-L., & Lai, M. (2001) · The Journal of Urology · doi:10.1097/00005392-200107000-00088 · Cited by 4
Mukherjee, S., Panda, S., Show, S., et al. (2022) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-022-03004-z · Cited by 4
Variable Regions of p53 Isoforms Allosterically Hard Code DNA Interaction
Armour-Garb, I., Han, I. S. M., Cowan, B. S., & Thayer, K. M. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c06229 · Cited by 4
Tumours and Tumour-Like Lesions
Ferrell, L. D., Kakar, S., Terracciano, L., & Wee, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8228-3.00013-2 · Cited by 6
Simulation in Education and Training: From Virtual Reality to Digital Twins
Silveira, I. F., Cardoso, A., & Martins, V. F. (2025) · Lecture notes in educational technology · doi:10.1007/978-981-96-3698-3_27 · Cited by 7
Cherneva, R. V., Georgiev, O. B., Petrov, D., et al. (2009) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2009.10817647 · Cited by 4
Wang, L., Zhao, T., Wang, S., Jin, J., Cai, Y., & Wang, F. (2019) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2019.1594674 · Cited by 4
Development of p53-targeting drugs that increase radioresistance in normal tissues
Ochi, S., Nishiyama, Y., & Morita, A. (2019) · The Journal of Medical Investigation · doi:10.2152/jmi.66.219 · Cited by 4
Analysis of Mutations in K-ras and p53 Genes in Sputum and Plasma Samples
Zhang, L., Gao, W., & Keohavong, P. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0223-2_22 · Cited by 4
Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53
Xirodimas, D. P., & Scheffner, M. (2010) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4419-6676-6_10 · Cited by 5
Baryshnikova, E. N., Balobanov, V. A., Katina, N., et al. (2007) · Molecular Biology · doi:10.1134/s0026893307040139 · Cited by 4
p73 – constitutively open for business
Seeliger, M. A., & Moll, U. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.56 · Cited by 4
Iijima, H., Kasai, N., Chiku, H., et al. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.1.41 · Cited by 4
Burr, P., Argyle, D. J., Reid, S., & Nasir, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202870 · Cited by 4
“Gene mutations within the DNA binding domain of p53 are the most prevalent mechanism of functional inactivation, occurring most frequently in the DNA binding domain of the protein (Cho et al., 1994).”
BackgroundChen, L., & Bateman, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2771 · Cited by 4
ller, P. M. O. (1995) · Stem Cells · doi:10.1002/stem.5530130729 · Cited by 4
A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification
Mejía, C., Pellı́n, A., Navarro, S., et al. (1999) · International Journal of Surgical Pathology · doi:10.1177/106689699900700304 · Cited by 4
“We also found a silent mutation in the 213 codon (CGA/CGG) that already has been described in neuroblastoma [24] and in other neoplasms [5] and is not related to cancer phenotype.”
BackgroundKumar, A., Joo, W. S., Meinke, G., Moine, S., Naumova, E. N., & Bullock, P. A. (2008) · Journal of Virology · doi:10.1128/jvi.00553-08 · Cited by 4
“loop 3 [9, 64]).”
Gottschalk, B., & Klein, A. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1643-5 · Cited by 5
“P53 binds as a tetramer (composed of a dimer of dimers) to p53 consensus sequences in the promoter region of target genes [9].”
BackgroundDNA Structure and Polymerase Fidelity: A New Role for A-DNA
Timsit, Y. (2000) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2000.10506617 · Cited by 4
Interaction of Tumor Suppressor p53 with DNA and Proteins
Wang, J., & Yang, J. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725366 · Cited by 4
“Each half-site contains 10 base pairs with a sequence of PuPuPuC(A/T)(T/A)GPyPyPy (where Pu and Py denote purines and pyrimidines, respectively [4, 15-21]).”
BackgroundSarin, H. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.714 · Cited by 4
P73, P63 and Mutant P53: Members of Protein Complexs Floating in Cancer Cells
Monti, O., Damalas, A., Strano, S., & Blandino, G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_10 · Cited by 4
Zampiga, V., Danesi, R., Tedaldi, G., Tebaldi, M., Cangini, I., Pirini, F., Pittureri, C., Amaducci, E., Guidi, L., Faedi, M., et al. (2016) · The International Journal of Biological Markers · doi:10.5301/jbm.5000227 · Cited by 4
“The protein with the R175H mutation failed to fold properly, resulting in a significant loss of transcriptional and tumor suppressive activity (13).”
BackgroundSemenza, J. C., & Weasel, L. H. (1997) · Environmental Health Perspectives · doi:10.2307/3433404 · Cited by 4
Computer Simulations of Peptides from the p53 DNA Binding Domain
Khalili, M., & Wales, D. J. (2009) · Journal of Chemical Theory and Computation · doi:10.1021/ct8005387 · Cited by 4
DNA binding and selective gene induction by different forms of the p53 protein
Mayelzadeh, F., & Martinez, J. D. (2006) · Oncogene · doi:10.1038/sj.onc.1210110 · Cited by 4
“The crystal structure of the p53 core domain bound to consensus DNA (Cho et al., 1994) has shown that the DNA-binding ability of p53 can be changed through two different mechanisms.”
BackgroundCORNER, B. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.566 · Cited by 4
The Li-Fraumeni syndrome and the role of TP53 mutations in predisposition to cancer
Birch, J. M. (1996) · Springer eBooks · doi:10.1007/978-1-4899-4501-3_8 · Cited by 4
p53-Mutationen und HPV-Infektionen in Plattenepithelkarzinomen der Kopf-Hals-Region
Riethdorf, S., Friedrich, R. E., Sühwold, J., et al. (1998) · Oral and Maxillofacial Surgery · doi:10.1007/s100060050024 · Cited by 4
“Die Mehrzahl der p53-Mutationen sind in den Exons 5–8 des p53-Gens lokalisiert, welche die DNA-bindende Domäne des Proteins kodieren [6].”
Background5′ Region and Exon 7 Mutations of the TP53 Gene in Two Cases of B-Cell Prolymphocytic Leukemia
Angeli, C. D., Cuneo, A., Aguiari, G., et al. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00101-0 · Cited by 4
The Immunomodulatory Activity of Peptides Related to the DNA Contacting Loop of p53 Protein
Bolewska‐Pedyczak, E., Siemion, I. Z., & Wieczorek, Z. J. (1996) · Journal of Peptide Science · doi:10.1002/psc.68 · Cited by 4
The Diels-Alder Reaction in Total Synthesis
Nicolaou, K. C., Snyder, S. A., Montagnon, T., & Vassilikogiannakis, G. E. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020517)41:10<1718::aid-anie1718>3.0.co;2-2 · Cited by 1,883
Binding of mutated Ras- and p53-derived peptides to HLA-DR molecules
Murakami, S., Yokomizo, H., Matsushita, S., et al. (1996) · Immunology Letters · doi:10.1016/0165-2478(96)02495-9 · Cited by 4
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.